A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Exclusion Criteria

• •History of life-threatening COPD, including admission to the intensive care unit and/or the need for intubation.
• •Screening for COPD acute exacerbations that require systemic hormone therapy prior to the visit.
• •Screening for hospitalization history due to COPD within the first 6 months.
• •Use antibiotics for respiratory tract infections within 6 weeks prior to screening or randomization visit.
• •Chest computed tomography (CT) revealed clinically significant abnormalities and concluded that the abnormalities were not caused by COPD.
• •Previous lung resection or lung reduction surgery.
• •Pulmonary rehabilitation treatment.
• •Previously received TQC3721 treatment.
• •Patients who received immunotherapy within the first 4 weeks of the screening period.
• •The patient has a history of diseases that are currently beyond their control.
• •History or current evidence of cardiovascular disease with clinical significance.
• •History of cured or untreated malignant tumors in any organ or system within the past 5 years.
• •Screening for clinically significant safety laboratory test outliers determined by the researcher during the visit.
• •Those who require oxygen therapy or intermittent oxygen therapy.
• •Receive attenuated live vaccine within 28 days prior to randomization, inactivated vaccine within 7 days, or study.
• •Planned vaccine recipients during the period.
• •Individuals who have participated in any drug or medical device clinical trials prior to screening.
• •Researchers believe that there are other situations that are not suitable for participation in the study.